Scribe Therapeutics enters September in a peculiar position — the stock has shed 7% on the week and 5% in a single session, yet four analyst initiations and a cluster of insider buying tell a sharply different story about where sentiment is heading.
The analyst angle here is the lead. Four firms kicked off coverage within the past two weeks, all with bullish ratings. HC Wainwright initiated at Buy on August 31 with a $60 target. Wells Fargo (Overweight, $60) and Guggenheim (Buy, $50) both came in on August 18. Leerink Partners is the outlier among the group — also Outperform, but with a more cautious $37 target. With the stock trading at $29, even the most conservative new initiation implies meaningful upside, and the consensus target of $57 sits nearly double the current price. The bull case rests on STX-1150's potential in cardiovascular and metabolic disease, a credible leadership team, and the cost-effectiveness argument for a gene-editing approach to high cholesterol. Bears counter that operating expenses are projected to exceed $100 million by FY2027 against a pre-revenue company, and clinical outcomes remain highly uncertain.
The insider register reinforces the bullish framing from the Street — and it is genuinely striking for a biotech of this size. Net insider buying over the past 90 days totalled roughly 3.7 million shares worth approximately $56 million. The single largest transaction was a $35 million open-market purchase by Behzad Aghazadeh on July 24 at $15 per share — the IPO price — followed by an additional $1.1 million purchase days later. OrbiMed put $15 million to work at the same price. The CFO and Chief Level Officer also participated at $15. Three separate Schedule 13D filings — from OrbiMed (7.2% stake), Eli Lilly (7.3%), and Aghazadeh (16.4%) — landed in late July and early July, placing activist-intent disclosures on the register for each. Eli Lilly's presence on the 13D register is particularly notable for a pure-play gene-editing platform. As always with Schedule 13D/G filings, stakes are as-last-disclosed around the 5% threshold, and holders can exit below that level without a further filing.
Short positioning is retreating rather than building, and the borrow market confirms the pressure has eased. Short interest fell 25% in a week to around 299,000 shares — a small absolute number even before considering the float — and availability has widened dramatically, jumping from roughly 223% two weeks ago to 713% as of September 1. That kind of expansion in available shares means the lending pool is far from stressed. Cost to borrow is still elevated at 26.6%, but it has been falling steadily from above 67% in late July, and the direction of travel is clearly lower. Together, the data points to shorts covering rather than adding pressure — consistent with the stock's 49% one-month gain, which itself suggests that much of the post-IPO short activity has already unwound. The ORTEX short score confirmed the shift, dropping sharply from around 62-63 through August to 51 on September 1 — a reading that no longer flags meaningful short-side pressure.
Scribe is a pre-revenue clinical-stage biotech, so conventional valuation multiples carry little explanatory weight. The negative PE and EV/EBITDA readings reflect the company's burn-rate reality rather than any investable signal. What the institutional register does show is that Avoro Capital and Andreessen Horowitz each entered at or near IPO with 16%-range stakes, and ARK Investment Management holds nearly 2%. That is a concentrated, high-conviction ownership structure — one where liquidity is thin and sentiment shifts can move the stock sharply in either direction.
The next scheduled earnings event is September 11. With no revenue and a pipeline in early-to-mid clinical stages, the print is unlikely to drive the stock on traditional metrics; pipeline updates, cash runway commentary, and any STX-1150 development milestones are what the new analyst cohort — and Eli Lilly's presence on the register — will be focused on.
See the live data behind this article on ORTEX.
Open SCTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
